Shionogi Europe Email Format
Pharmaceutical ManufacturingNorth Holland, Netherlands201-500 Employees
Shionogi B.V. (known as “Shionogi Europe”) is the European headquarters of Shionogi & Co., Ltd, a leading global research-driven pharmaceutical company based in Osaka, Japan. Since 1878, Shionogi has been striving to supply the best possible medicines to protect the health and wellbeing of the patients we serve. We are dedicated to finding innovative solutions for pressing unmet clinical needs, and have a strong track record in discovering and developing novel medicines for antimicrobial resistance (AMR), HIV and influenza. Alongside our work in infectious diseases, we also have extensive expertise in other areas of unmet clinical needs within our Hospital Specialty Business, and a strong track record in other therapy areas affecting quality of life, particularly Women’s Health. Since launching in Europe in 2012, we have significantly expanded our presence and now have coverage of the biggest markets in the continent. Our offices in Amsterdam, Berlin, London, Madrid, Paris and Rome provide the bases for over 300 passionate staff from across the spectrum of big pharma and biotech, as well as experts in technology, creatives, entrepreneurs and others - who come together to do things differently and better. Our culture is unique, blending our Japanese roots with our strong and rapidly growing European operation. We have a friendly, inclusive work environment and aim to foster a culture that encourages our people to break out of the boundaries of the traditional pharmaceutical company. Through successful strategic partnerships and open collaboration, we are determined to shape the future of healthcare. Our ambitious growth plans include extending the reach of our marketed products, developing our innovative pipeline of medicines and securing the right partnerships and acquisitions to accelerate our development. To find out about partnering with us, visit: https://t.ly/YzlSu For career opportunities, visit: https://t.ly/mERcQ NP-EU-NP-0303 DOP July 2024